Fractyl Health gains as experimental procedure helps maintain weight-loss in study

** Shares of drug developer Fractyl Health GUTS.O rise 15.9% to $1.16

** Co says patients treated with its experimental lead product Revita preserved weight loss after GLP-1 drug discontinuation

** Revita is an outpatient endoscopic procedure designed to modify dysfunction in the part of the small intestine through hydrothermal ablation in order to restore metabolic health

** At 3 months, those treated with Revita lost an additional 2.5% total body weight after stopping Eli Lilly's LLY.N tirzepatide, the active ingredient in its blockbuster obesity drug Zepbound, while those who had a sham procedure regained 10%

** Including session's move, stock down 45.8% YTD